Abstract
The effect of aging on carbamazepine (CBZ) plasma level/dose ratio was evaluated retrospectively in 15 children who were receiving CBZ monotherapy and who were followed up for at least 3 years. Subjects of the study were selected from a population of roughly 4,500 patients attending our therapeutic drug monitoring service during a 12-year period. Results showed that the CBZ plasma level/dose ratio increases within subject during childhood, in agreement with data obtained in between-patient studies. However, the increase is not linear with age, the greatest modifications being observed between 9 and 13 years of age. Weight gain alone does not seem to explain this finding, implicating the involvement of complex physiological changes occurring during puberty.
| Original language | English |
|---|---|
| Pages (from-to) | 457-460 |
| Number of pages | 4 |
| Journal | Therapeutic Drug Monitoring |
| Volume | 14 |
| Issue number | 6 |
| Publication status | Published - 1992 |
Fingerprint
Keywords
- Carbamazepine
- Children
- Epilepsy
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology
- Biochemistry, Genetics and Molecular Biology(all)
- Biochemistry
- Health, Toxicology and Mutagenesis
- Public Health, Environmental and Occupational Health
- Toxicology
Cite this
A within-subject analysis of carbamazepine disposition related to development in children with epilepsy. / Albani, Fiorenzo; Riva, Roberto; Contin, Manuela; Baruzzi, Agostino.
In: Therapeutic Drug Monitoring, Vol. 14, No. 6, 1992, p. 457-460.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A within-subject analysis of carbamazepine disposition related to development in children with epilepsy
AU - Albani, Fiorenzo
AU - Riva, Roberto
AU - Contin, Manuela
AU - Baruzzi, Agostino
PY - 1992
Y1 - 1992
N2 - The effect of aging on carbamazepine (CBZ) plasma level/dose ratio was evaluated retrospectively in 15 children who were receiving CBZ monotherapy and who were followed up for at least 3 years. Subjects of the study were selected from a population of roughly 4,500 patients attending our therapeutic drug monitoring service during a 12-year period. Results showed that the CBZ plasma level/dose ratio increases within subject during childhood, in agreement with data obtained in between-patient studies. However, the increase is not linear with age, the greatest modifications being observed between 9 and 13 years of age. Weight gain alone does not seem to explain this finding, implicating the involvement of complex physiological changes occurring during puberty.
AB - The effect of aging on carbamazepine (CBZ) plasma level/dose ratio was evaluated retrospectively in 15 children who were receiving CBZ monotherapy and who were followed up for at least 3 years. Subjects of the study were selected from a population of roughly 4,500 patients attending our therapeutic drug monitoring service during a 12-year period. Results showed that the CBZ plasma level/dose ratio increases within subject during childhood, in agreement with data obtained in between-patient studies. However, the increase is not linear with age, the greatest modifications being observed between 9 and 13 years of age. Weight gain alone does not seem to explain this finding, implicating the involvement of complex physiological changes occurring during puberty.
KW - Carbamazepine
KW - Children
KW - Epilepsy
UR - http://www.scopus.com/inward/record.url?scp=0026446412&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026446412&partnerID=8YFLogxK
M3 - Article
C2 - 1485365
AN - SCOPUS:0026446412
VL - 14
SP - 457
EP - 460
JO - Therapeutic Drug Monitoring
JF - Therapeutic Drug Monitoring
SN - 0163-4356
IS - 6
ER -